Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Entrada Therapeutics (Nasdaq: TRDA) announced that Nathan Dowden, Chief Operating Officer, will virtually present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be accessible starting September 12, 2022, at 7:00 a.m. Eastern Time on the company's website. A replay will be available for 90 days after the event. Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics for treating diseases including Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA) announced that it is on track to submit an Investigational New Drug (IND) application for ENTR-601-44, targeting Duchenne muscular dystrophy (DMD), in Q4 2022. The company holds $244 million in cash and equivalents, ensuring a cash runway into 2H 2024. R&D expenses surged to $16.2 million from $6.8 million year-over-year, with a net loss of $23.2 million for Q2 2022. Entrada also presented promising preclinical data for its therapeutic candidates and initiated collaborations aimed at accelerating developments in neuromuscular disease treatments.
Entrada Therapeutics (Nasdaq: TRDA) has announced a collaboration with the Myotonic Dystrophy Clinical Research Network (DMCRN) to support the END-DM1 study, which aims to understand disease progression in myotonic dystrophy type 1 (DM1). This non-interventional study will provide critical data for future clinical trials. Entrada's clinical candidate, ENTR-701, is being developed to potentially treat DM1, with new preclinical data indicating improved therapeutic effects in mouse models. The company plans to file an IND application for ENTR-701 in 2023.
Entrada Therapeutics (Nasdaq: TRDA) announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald, previously the Vice President of Corporate Communications and Investor Relations, will report to Dipal Doshi, President and CEO. Her extensive experience in biopharmaceutical communications and stakeholder engagement supports Entrada's focus on developing Endosomal Escape Vehicle (EEV™) therapeutics, particularly for neuromuscular diseases like Duchenne muscular dystrophy. The company is transitioning into a clinical stage entity this year.
Entrada Therapeutics (Nasdaq: TRDA) announced its participation at the William Blair Biotech Focus Conference in New York on July 12-13, 2022. A fireside chat featuring Dipal Doshi and Natarajan Sethuraman will be available for viewing starting July 11, 2022, at 9:00 a.m. ET on the company’s website, with a 90-day replay. Entrada focuses on developing Endosomal Escape Vehicle (EEV™) therapeutics to target previously inaccessible intracellular sites, targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company focused on advancing Endosomal Escape Vehicle (EEV™) therapeutics, announced its participation in the Goldman Sachs Global Healthcare Conference. The event will feature a fireside chat with President and CEO Dipal Doshi on June 14, 2022, at 2:40 p.m. PT in Rancho Palos Verdes, CA. A live webcast will be available on the company’s website, with a replay accessible for 90 days afterward.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its second clinical candidate, ENTR-701, aimed at treating myotonic dystrophy type 1. The company is on track to submit an Investigational New Drug application for ENTR-601-44, targeting Duchenne muscular dystrophy, in Q4 2022. As of March 31, 2022, Entrada has $263.9 million in cash and equivalents, projecting sufficient funds to support operations into the second half of 2024. However, the first quarter of 2022 reported a net loss of $21.7 million, significantly higher than the $8.4 million loss in Q1 2021.
Entrada Therapeutics (Nasdaq: TRDA) has shared promising non-human primate data for its lead candidate, ENTR-601-44, indicating a durability of response for 12 weeks in treating Duchenne muscular dystrophy (DMD). The company also introduced ENTR-701, targeted at myotonic dystrophy type 1 (DM1). Both candidates are set for Investigational New Drug applications: ENTR-601-44 in Q4 2022 and ENTR-701 in 2023. These advancements reinforce Entrada's commitment to developing intracellular therapeutics with potential for transformative patient outcomes.
Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be accessible starting May 23, 2022, at 7:00 a.m. ET on the company's website. A replay will be available for 90 days after the event.
Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics to deliver medicines intracellularly, particularly for conditions like Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA) reported financial results for the fourth quarter and full year ending December 31, 2021. The company secured approximately $209 million from its IPO and held $291.1 million in cash as of year-end. Planned developments include submitting an IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in the second half of 2022. R&D expenses rose to $12.4 million for Q4 2021, with a net loss of $18.4 million. G&A expenses also increased significantly, reflecting higher personnel and professional fees.